Oral Abstract Session 01 - Global HIV Vaccine Enterprise

Symposium 04: Cross-cutting Issues in Clinical Trial Design
S04.03
Combination Prevention: Scaling Up Delivery While
Accelerating Discovery, Lessons From Medical Male
Circumcision in Kenya
K Agot 1 , E Omanga 1
1 University of Washington, Seattle, WA, USA
The presentation will focus on combination HIV prevention
programs being implemented in Kenya, the complementary role
each is playing individually and collectively and the synergies
arising therefrom, as well as the challenges faced in scaling them
up. Using the rollout of voluntary medical male circumcision
(VMMC) in Kenya as a case study, the presentation will delve into
how the positive results of VMMC was just the beginning of a
series of new discoveries that have helped to strengthen the scale
up to its current heights of inching towards the half-million mark
by the close of 2012. Scaling up VMMC service delivery while
accelerating further discovery underscore the point that the
breakthroughs in the HIV prevention field in the last three years
are refreshing news but are by no means a call to complacency.
With each new discovery in HIV prevention should be a fresh call
to design even more studies, look for newer/better answers, and
improve the delivery and uptake of what we have available.
S04.04
Symposia Sessions
Combination Prevention: Designing and
Implementing a New Era of Trials
R. Barnabast 1
1 University of Washington, Seattle, WA, USA
How to measure the impact of HIV combination prevention
programs is a central question for public health efforts to control
HIV epidemic spread. Implicit in this question is how intensive
do prevention programs need to be to reduce HIV incidence? To
answer these questions, three large community randomized trials
are planned to evaluate HIV combination prevention approaches
in South Africa, Zambia, Tanzania and Botswana. All propose to
use intensified methods of HIV testing (two are using homebased
testing) to increase testing coverage, knowledge of status
and linkage to care including antiretroviral therapy. The main
outcome for the studies is the change in HIV incidence in the
intervention communities compared to the control communities.
Ongoing monitoring, evaluation and modeling analyses could
help studies reach their goals and adapt their design to achieve
their primary objectives. Also, the data from these studies will
provide insight into implementation strategies moving forward.
AIDS Vaccine 2012
39
SYMPOSIA SESSIONS